Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina

Autores
Gutiérrez, Silvina Elena; Rivero, Mariana Alejandra; Rodríguez, Marcelo; Estein, Silvia Marcela
Año de publicación
2022
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Mass vaccination has been the key element in controlling the COVID-19 pandemic. Vaccination in Tandil began in January 2021 for health care workers, which mainly received Sputnik V (SpV). The inactivated vaccine from Sinopharm (Si) and the ChAdOs-1S vaccine from AstraZeneca (AZ) were available since March 2021. We aimed to measure and compare anti-SARS CoV-2 spike (S) antibodies in naïve and seropositive individuals after receiving first and second dose of different vaccines.A total of 141 individuals were recruited between January and August 2021. Serum samples were obtained before vaccination and after each vaccine dose. Specific anti-S antibodies were quantified using the COVIDAR IgG ELISA. Results were log transformed and a repeated measures ANOVA was adjusted. Seventy one of the individuals had detectable anti-S antibodies due to previous infection while 70 were seronegative before receiving the first dose (initial status). Fifty four from 71 (76%) of the initially seronegative participants seroconverted after the first dose. All but one of the non-seroconverters received the Si vaccine. After the second dose 95.8% of the participants seroconverted. Differences were observed depending on the initial status, type of vaccine and number of doses received (p= 0.0017). The titer of antibodies elicited against the 1° dose was influenced by the initial status of the individual for the 3 vaccines. After the vaccination scheme was completed, there were also differences in the level of specific antibodies achieved depending on the initial status in those who received the Adenovirus vectored vaccines. Both in naïve and sensitized participants SpV and AZ induced higher levels of antibodies compared to Si (p> 0.05). Sinopharm resulted the less immunogenic vaccine. This result may be due to the interval between shots, which was 47 days mean, instead of the recommended 21-30 days. Therefore, individual with 2 doses of Si may be benefited with heterologous booster.
Fil: Gutiérrez, Silvina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; Argentina
Fil: Rivero, Mariana Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; Argentina
Fil: Rodríguez, Marcelo. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; Argentina
Fil: Estein, Silvia Marcela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; Argentina
LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual la Sociedad Argentina de Inmunología; 3° Congreso Franco-Argentino de Inmunología; Reunión Anual de la Sociedad Argentina de Fisiología
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Sociedad Argentina de Inmunología
Sociedad Argentina de Fisiología
Materia
COVID-19
VACCINES
PANDEMIC
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/224919
Acceder
id CONICETDig_cdbc2d5f5def51deff1601238229cda9
oai_identifier_str oai:ri.conicet.gov.ar:11336/224919
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, ArgentinaGutiérrez, Silvina ElenaRivero, Mariana AlejandraRodríguez, MarceloEstein, Silvia MarcelaCOVID-19VACCINESPANDEMIChttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Mass vaccination has been the key element in controlling the COVID-19 pandemic. Vaccination in Tandil began in January 2021 for health care workers, which mainly received Sputnik V (SpV). The inactivated vaccine from Sinopharm (Si) and the ChAdOs-1S vaccine from AstraZeneca (AZ) were available since March 2021. We aimed to measure and compare anti-SARS CoV-2 spike (S) antibodies in naïve and seropositive individuals after receiving first and second dose of different vaccines.A total of 141 individuals were recruited between January and August 2021. Serum samples were obtained before vaccination and after each vaccine dose. Specific anti-S antibodies were quantified using the COVIDAR IgG ELISA. Results were log transformed and a repeated measures ANOVA was adjusted. Seventy one of the individuals had detectable anti-S antibodies due to previous infection while 70 were seronegative before receiving the first dose (initial status). Fifty four from 71 (76%) of the initially seronegative participants seroconverted after the first dose. All but one of the non-seroconverters received the Si vaccine. After the second dose 95.8% of the participants seroconverted. Differences were observed depending on the initial status, type of vaccine and number of doses received (p= 0.0017). The titer of antibodies elicited against the 1° dose was influenced by the initial status of the individual for the 3 vaccines. After the vaccination scheme was completed, there were also differences in the level of specific antibodies achieved depending on the initial status in those who received the Adenovirus vectored vaccines. Both in naïve and sensitized participants SpV and AZ induced higher levels of antibodies compared to Si (p> 0.05). Sinopharm resulted the less immunogenic vaccine. This result may be due to the interval between shots, which was 47 days mean, instead of the recommended 21-30 days. Therefore, individual with 2 doses of Si may be benefited with heterologous booster.Fil: Gutiérrez, Silvina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; ArgentinaFil: Rivero, Mariana Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; ArgentinaFil: Rodríguez, Marcelo. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; ArgentinaFil: Estein, Silvia Marcela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; ArgentinaLXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual la Sociedad Argentina de Inmunología; 3° Congreso Franco-Argentino de Inmunología; Reunión Anual de la Sociedad Argentina de FisiologíaMar del PlataArgentinaSociedad Argentina de Investigación ClínicaSociedad Argentina de InmunologíaSociedad Argentina de FisiologíaFundación Revista Medicina2022info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/224919Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina; LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual la Sociedad Argentina de Inmunología; 3° Congreso Franco-Argentino de Inmunología; Reunión Anual de la Sociedad Argentina de Fisiología; Mar del Plata; Argentina; 2022; 333-3331669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com/revistas/vol82-22/s5/1s5.pdfInternacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:56:29Zoai:ri.conicet.gov.ar:11336/224919instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:56:29.504CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina
title Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina
spellingShingle Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina
Gutiérrez, Silvina Elena
COVID-19
VACCINES
PANDEMIC
title_short Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina
title_full Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina
title_fullStr Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina
title_full_unstemmed Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina
title_sort Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina
dc.creator.none.fl_str_mv Gutiérrez, Silvina Elena
Rivero, Mariana Alejandra
Rodríguez, Marcelo
Estein, Silvia Marcela
author Gutiérrez, Silvina Elena
author_facet Gutiérrez, Silvina Elena
Rivero, Mariana Alejandra
Rodríguez, Marcelo
Estein, Silvia Marcela
author_role author
author2 Rivero, Mariana Alejandra
Rodríguez, Marcelo
Estein, Silvia Marcela
author2_role author
author
author
dc.subject.none.fl_str_mv COVID-19
VACCINES
PANDEMIC
topic COVID-19
VACCINES
PANDEMIC
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Mass vaccination has been the key element in controlling the COVID-19 pandemic. Vaccination in Tandil began in January 2021 for health care workers, which mainly received Sputnik V (SpV). The inactivated vaccine from Sinopharm (Si) and the ChAdOs-1S vaccine from AstraZeneca (AZ) were available since March 2021. We aimed to measure and compare anti-SARS CoV-2 spike (S) antibodies in naïve and seropositive individuals after receiving first and second dose of different vaccines.A total of 141 individuals were recruited between January and August 2021. Serum samples were obtained before vaccination and after each vaccine dose. Specific anti-S antibodies were quantified using the COVIDAR IgG ELISA. Results were log transformed and a repeated measures ANOVA was adjusted. Seventy one of the individuals had detectable anti-S antibodies due to previous infection while 70 were seronegative before receiving the first dose (initial status). Fifty four from 71 (76%) of the initially seronegative participants seroconverted after the first dose. All but one of the non-seroconverters received the Si vaccine. After the second dose 95.8% of the participants seroconverted. Differences were observed depending on the initial status, type of vaccine and number of doses received (p= 0.0017). The titer of antibodies elicited against the 1° dose was influenced by the initial status of the individual for the 3 vaccines. After the vaccination scheme was completed, there were also differences in the level of specific antibodies achieved depending on the initial status in those who received the Adenovirus vectored vaccines. Both in naïve and sensitized participants SpV and AZ induced higher levels of antibodies compared to Si (p> 0.05). Sinopharm resulted the less immunogenic vaccine. This result may be due to the interval between shots, which was 47 days mean, instead of the recommended 21-30 days. Therefore, individual with 2 doses of Si may be benefited with heterologous booster.
Fil: Gutiérrez, Silvina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; Argentina
Fil: Rivero, Mariana Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; Argentina
Fil: Rodríguez, Marcelo. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; Argentina
Fil: Estein, Silvia Marcela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Sanidad Animal y Medicina Preventiva; Argentina
LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual la Sociedad Argentina de Inmunología; 3° Congreso Franco-Argentino de Inmunología; Reunión Anual de la Sociedad Argentina de Fisiología
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Sociedad Argentina de Inmunología
Sociedad Argentina de Fisiología
description Mass vaccination has been the key element in controlling the COVID-19 pandemic. Vaccination in Tandil began in January 2021 for health care workers, which mainly received Sputnik V (SpV). The inactivated vaccine from Sinopharm (Si) and the ChAdOs-1S vaccine from AstraZeneca (AZ) were available since March 2021. We aimed to measure and compare anti-SARS CoV-2 spike (S) antibodies in naïve and seropositive individuals after receiving first and second dose of different vaccines.A total of 141 individuals were recruited between January and August 2021. Serum samples were obtained before vaccination and after each vaccine dose. Specific anti-S antibodies were quantified using the COVIDAR IgG ELISA. Results were log transformed and a repeated measures ANOVA was adjusted. Seventy one of the individuals had detectable anti-S antibodies due to previous infection while 70 were seronegative before receiving the first dose (initial status). Fifty four from 71 (76%) of the initially seronegative participants seroconverted after the first dose. All but one of the non-seroconverters received the Si vaccine. After the second dose 95.8% of the participants seroconverted. Differences were observed depending on the initial status, type of vaccine and number of doses received (p= 0.0017). The titer of antibodies elicited against the 1° dose was influenced by the initial status of the individual for the 3 vaccines. After the vaccination scheme was completed, there were also differences in the level of specific antibodies achieved depending on the initial status in those who received the Adenovirus vectored vaccines. Both in naïve and sensitized participants SpV and AZ induced higher levels of antibodies compared to Si (p> 0.05). Sinopharm resulted the less immunogenic vaccine. This result may be due to the interval between shots, which was 47 days mean, instead of the recommended 21-30 days. Therefore, individual with 2 doses of Si may be benefited with heterologous booster.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/224919
Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina; LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual la Sociedad Argentina de Inmunología; 3° Congreso Franco-Argentino de Inmunología; Reunión Anual de la Sociedad Argentina de Fisiología; Mar del Plata; Argentina; 2022; 333-333
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/224919
identifier_str_mv Immunogenicity of Sputnik V, BBIBP-CorV and ChAdOx-1S vaccines in naïve and previously infected individuals from Tandil, Argentina; LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual la Sociedad Argentina de Inmunología; 3° Congreso Franco-Argentino de Inmunología; Reunión Anual de la Sociedad Argentina de Fisiología; Mar del Plata; Argentina; 2022; 333-333
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com/revistas/vol82-22/s5/1s5.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Internacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269404943876096
score 13.13397

Publicaciones similares